Gabriela Halder, MD
Urogynecology and Reconstructive Pelvic Surgery · Birmingham, ALNPI 1831517291
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,831 of the $3,226 with a category attached, or 87.8%. 6 manufacturers reported payments, led by Boston Scientific at 56.1% of the total. Reporting peaked in 2023 at $910 and has fallen 51.9% since, to $438 in 2025.
Across 41 payments — averaging $78.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Coloplast$394
- Medtronic$381
- Caldera Medical, Inc$298
- Axonics, Inc.$290
- Bluewind Medical$52
What the payments were for
- Grants$39412%
- Food & beverage$2,83188%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 17 | $1,810 |
| Coloplast | 8 | $394 |
| Medtronic(2 entities) | 5 | $381 |
| Caldera Medical, Inc | 6 | $298 |
| Axonics, Inc. | 4 | $290 |
| Bluewind Medical | 1 | $52 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL PELVIC ORGAN PROLAPSE$356
- Advantage System$286
- Solyx SIS System$263
- Axonics$235
- UPSYLON$161
- ALTIS$137
- Desara$137
- INTERSTIM$132
- RESTORELLE$112
- SOLYX$110
How this compares
Too few urogynecology and reconstructive pelvic surgery providers in Alabamato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 59 | $3,854 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 29 | $237 |
Paid to pharmacies, not to this prescriber.
Other urogynecology and reconstructive pelvic surgery in Birmingham
- Brent ParnellBirmingham$208K
- David EllingtonBirmingham$9K
- Celia KuceraBirmingham$406
- Charles HanesMobile$28K
- Himanshu AggarwalMontgomery$19K
- George FahyBay Minette$14K
- Alison PickeringHomewood$11K
- Vincent ScottMobile$10K
- Robert BrownMobile$8K
- Nicole MassieHomewood$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.